Viracor Eurofins gets EUA for SARS-CoV-2 LDT

written by CAP TODAY
May 19, 2020

May 2020—Viracor Eurofins was granted FDA emergency use authorization for the Viracor SARS-CoV-2 assay, a real-time polymerase chain reaction test intended for the qualitative detection of SARS-CoV-2 viral RNA in nasopharyngeal swab, nasal swab, nasopharyngeal wash, nasal wash, oropharyngeal swab, and bronchoalveolar lavage from individuals suspected of having COVID-19.

Results are available one to two days from specimen receipt.

In a separate release, the company announced its Eurofins' U.S. Clinical Diagnostics network began COVID-19 antibody testing at Boston Heart Diagnostics, a Eurofins subsidiary. The company also announced it is partnering with the National Kidney Registry to deliver COVID-19 antibody testing for NKR's network of member centers.

Viracor Eurofins, 800-305-5198

©2026 CAP TODAY, all rights reserved.